Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



China, Mainland M0 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)A:--
F: --
P: --
India CPI YoY (Nov)A:--
F: --
P: --
India Deposit Gowth YoYA:--
F: --
P: --
Brazil Services Growth YoY (Oct)A:--
F: --
P: --
Mexico Industrial Output YoY (Oct)A:--
F: --
P: --
Russia Trade Balance (Oct)A:--
F: --
P: --
Philadelphia Fed President Henry Paulson delivers a speech
Canada Building Permits MoM (SA) (Oct)A:--
F: --
P: --
Canada Wholesale Sales YoY (Oct)A:--
F: --
P: --
Canada Wholesale Inventory MoM (Oct)A:--
F: --
P: --
Canada Wholesale Inventory YoY (Oct)A:--
F: --
P: --
Canada Wholesale Sales MoM (SA) (Oct)A:--
F: --
P: --
Germany Current Account (Not SA) (Oct)A:--
F: --
P: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
Japan Tankan Small Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Small Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large-Enterprise Capital Expenditure YoY (Q4)A:--
F: --
P: --
U.K. Rightmove House Price Index YoY (Dec)A:--
F: --
P: --
China, Mainland Industrial Output YoY (YTD) (Nov)A:--
F: --
P: --
China, Mainland Urban Area Unemployment Rate (Nov)A:--
F: --
P: --
Saudi Arabia CPI YoY (Nov)A:--
F: --
P: --
Euro Zone Industrial Output YoY (Oct)A:--
F: --
P: --
Euro Zone Industrial Output MoM (Oct)A:--
F: --
P: --
Canada Existing Home Sales MoM (Nov)A:--
F: --
P: --
Euro Zone Total Reserve Assets (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
Canada New Housing Starts (Nov)--
F: --
P: --
U.S. NY Fed Manufacturing Employment Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing Index (Dec)--
F: --
P: --
Canada Core CPI YoY (Nov)--
F: --
P: --
Canada Manufacturing Unfilled Orders MoM (Oct)--
F: --
P: --
U.S. NY Fed Manufacturing Prices Received Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing New Orders Index (Dec)--
F: --
P: --
Canada Manufacturing New Orders MoM (Oct)--
F: --
P: --
Canada Core CPI MoM (Nov)--
F: --
P: --
Canada Trimmed CPI YoY (SA) (Nov)--
F: --
P: --
Canada Manufacturing Inventory MoM (Oct)--
F: --
P: --
Canada CPI YoY (Nov)--
F: --
P: --
Canada CPI MoM (Nov)--
F: --
P: --
Canada CPI YoY (SA) (Nov)--
F: --
P: --
Canada Core CPI MoM (SA) (Nov)--
F: --
P: --
Canada CPI MoM (SA) (Nov)--
F: --
P: --
Federal Reserve Board Governor Milan delivered a speech
U.S. NAHB Housing Market Index (Dec)--
F: --
P: --
Australia Composite PMI Prelim (Dec)--
F: --
P: --
Australia Services PMI Prelim (Dec)--
F: --
P: --
Australia Manufacturing PMI Prelim (Dec)--
F: --
P: --
Japan Manufacturing PMI Prelim (SA) (Dec)--
F: --
P: --
U.K. 3-Month ILO Employment Change (Oct)--
F: --
P: --
U.K. Unemployment Claimant Count (Nov)--
F: --
P: --
U.K. Unemployment Rate (Nov)--
F: --
P: --
U.K. 3-Month ILO Unemployment Rate (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Including Bonuses) YoY (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Excluding Bonuses) YoY (Oct)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the “Neutral” zone on Thursday.
U.S. stocks closed lower on Thursday, with the Dow Jones index falling more than 500 points during the session.
On the economic data front, U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000. The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June.
Abbott Laboratories reported better-than-expected earnings for its second quarter on Thursday. D.R. Horton, Inc. reported stronger-than-expected second-quarter earnings.
Most sectors on the S&P 500 closed on a negative note, with healthcare, consumer discretionary and financials stocks recording the biggest losses on Thursday. However, energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 533 points to 40,665.02 on Thursday. The S&P 500 fell 0.78% at 5,544.59, while the Nasdaq Composite dipped 0.70% at 17,871.22 during Thursday's session.
Investors are awaiting earnings results from American Express Company , Schlumberger Limited and Halliburton Company today.
What is CNN Business Fear & Greed Index?
At a current reading of 50.6, the index moved to the “Neutral” zone on Thursday, versus a prior reading of 59.
The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
Stocks Photo by Phongphan on Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Health care stocks were retreating late Thursday afternoon, with the NYSE Health Care Index falling 2.5% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.3%.
The iShares Biotechnology ETF (IBB) shed 1.7%.
In corporate news, Cassava Sciences shares jumped 5.1% after the Delaware Court of Chancery scheduled a hearing to dismiss a lawsuit against the company's officers.
Silo Pharma shares surged 57% as it said Thursday it entered into a device and development master plan with medical technology provider Resyca.
Abbott Laboratories reported bigger-than-expected increases in Q2 results amid revenue growth in medical device and nutrition, and the company raised its full-year earnings forecast. The shares fell 4.5%.
Agenus shares plunged nearly 59% after the US Food and Drug Administration advised against an accelerated approval pathway for the company's potential colorectal cancer combination treatment.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.
The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48.
Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Leading and Lagging Sectors
Energy shares jumped by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 1.6%.
Top Headline
Abbott Laboratories reported better-than-expected earnings for its second quarter on Thursday.
The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
Abbott said it projects full-year 2024 GAAP EPS of $3.30-$3.40 versus prior guidance of $3.25-$3.40, primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. The company forecasts adjusted EPS of $4.61-$4.71 versus the prior guidance of $4.55-$4.70 and consensus of $4.63.
Equities Trading UP
Equities Trading DOWN
Also Check This Out: Nvidia, Electronic Arts And 2 Other Stocks Insiders Are Selling
Commodities
In commodity news, oil traded up 0.5% to $83.23 while gold traded down 0.1% at $2,458.60.
Silver traded down 0.5% to $30.225 on Thursday, while copper fell 2.9% to $4.2815.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 fell 0.16%, Germany's DAX fell 0.45% and France's CAC 40 rose 0.21%. Spain's IBEX 35 Index rose 0.38%, while London's FTSE 100 rose 0.21%.
Construction output in the Eurozone fell 2.4% year-over-year in May compared to a revised 1.5% decline in the prior month. Passenger car registrations in the European Union climbed 4.3% year-over-year to 1.1 million units in June.
Regular pay in the U.K., excluding bonus payment, rose 5.7% year-over-year to GBP 643/week during the three months to May, while the unemployment rate came in unchanged at 4.4% from March to May.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.36%, Hong Kong's Hang Seng Index gaining 0.22%, China's Shanghai Composite Index gaining 0.48% and India's S&P BSE Sensex climbing 0.78%.
Hong Kong’s unemployment rate came in unchanged at 3% during the three months ending June. Japan reported a trade surplus of JPY 224.04 billion in June, compared to market views for a deficit of JPY 240 billion.
Economics
Now Read This:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels last seen in late April.
Both the S&P 500 and the Nasdaq 100 indices declined by 0.6%, while the Dow Jones Industrial Average fell 0.7%, potentially ending a streak of six consecutive positive sessions.
Small-cap stocks also succumbed to the broader negative sentiment, with the Russell 2000 index dropping 0.7%.
Chicago Fed President Austan Goolsbee, a known “dove” on the board, expressed optimism about progress on inflation and the U.S. economy’s resilience in avoiding a recession. He did not commit to a potential rate cut in September.
Following Wednesday’s sell-off triggered by concerns over increased U.S. chip export restrictions to China, semiconductor stocks remained broadly weaker, with the iShares Semiconductor ETF down by 0.6%. Despite this, Nvidia Corp. defied the trend, rising 1.8%.
Significant volatility erupted in the health care sector, particularly within the weight loss drug industry. The market duopoly of Eli Lilly and Company and Novo Nordisk A/S face heightened competitive threats from Pfizer Inc. and Roche Holding Ltd , both of which recently announced developments to enter this lucrative market.
Shares of Eli Lilly plunged 5.6%, marking their worst session since mid-March 2021, while Novo Nordisk shares dropped 5%, their worst performance since August 2022.
On the economic data front, jobless claims rose more than expected last week and continuing claims reached their highest level since November 2021, indicating a cooling trend in the labor market.
The U.S. dollar acted as a safe haven, rising 0.3%, while Treasury yields inched higher across the curve. The European Central Bank kept interest rates unchanged, as expected, keeping the door open for September.
In commodities, growth-sensitive copper tumbled over 3%, hitting its lowest level since mid-April. Silver eased by 0.9% and gold remained flat. Oil prices slipped 0.3%, while natural gas surged over 4%, nearly recouping Wednesday’s sharp losses following a weaker-than-expected buildup in inventories last week.
Bitcoin edged 0.4% lower, eyeing a second consecutive negative close.
Thursday’s Performance In Major US Indices, ETFs
| Major Indices | Price | 1-day %chg |
| Nasdaq 100 | 19,687.70 | -0.6% |
| S&P 500 | 5,556.41 | -0.6% |
| Dow Jones | 40,929.46 | -0.7% |
| Russell 2000 | 2,220.63 | -0.7% |
According to Benzinga pro data:
Thursday’s Market Movers
Read now:
Photo via Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
By Leroy Leo and Puyaan Singh
July 18 (Reuters) - Abbott Laboratories ABT.N will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Ford said on Thursday.
The company plans to launch the over-the-counter device, Lingo, this year. It could be a multi-billion-dollar product for Abbott, Ford estimated, adding it was still in its early days.
Lingo and Libre Rio, another of Abbott's devices, received clearance from the U.S. Food and Drug Administration's last month.
Lingo targets consumers who want to better understand their health, while Libre Rio is for adults with type 2 diabetes who do not need insulin.
Abbott is a key player in the market for continuous glucose monitors sold under prescription to diabetes patients, along with rivals DexCom DXCM.O and Medtronic MDT.N.
FreeStyle Libre, Abbott's blood sugar monitor, generated $1.6 billion in sales globally in the second quarter. However, the company said the marketing for a consumer product would greatly differ from that for a medical device.
"I don't think, given our experience here, that you can just go on TV, blast TV advertising and you'll get this big uptake. You are going to have to do some on-the-ground kind of guerilla marketing," Ford said during an analyst conference call.
Guerilla marketing uses tactics such as on-ground outreach, social media campaigns, among others, and usually involve low budgets.
Ford expects sales growth for Lingo to ramp up over time as the company builds the market.
RBC Capital Markets analyst Shagun Singh does not currently model much in sales of Abbott and Dexcom's OTC products, but believes the market would be significant.
Abbott is "literally just launching it this summer. So there will be a lot to learn for us, but substantial opportunities for both companies," said Singh.
(Reporting by Leroy Leo and Puyaan Singh in Bengaluru; Editing by Shreya Biswas)
(( Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7; ))
Keywords: ABBOTT-GLUCOSE MONITORS/
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up